November 28, 2021

Side Effects Bimatoprost 0.03% Ophthalmic Solution

By admin



Adverse reactions Bimatoprost 0.03%

In the course of a clinical study, adverse reactions occurred in approximately 38% of patients who were treated with Bimatoprost 0.03%  eye drops, 0.1 mg / ml. The most common adverse reaction (in 29% of patients) was conjunctival hyperemia (mainly mild and non-inflammatory). Approximately 4% of patients stopped using the drug due to a side effect that occurred during the study.

During clinical trials of Bimatoprost 0.03%  eye drops, 0.1 mg/ml, the following were found adverse reactions. Most of them were from the side of the organs of vision, had a light form and none was heavy.

In the course of clinical studies, the possibility of hair growth was discovered in areas of the skin where the drug constantly comes into contact with the skin.

The frequency of adverse reactions is determined as follows:

  • very often (≥1/10); often (from ≥1/100 to <1/10);
  • infrequently (from ≥1/1000 to <1/100),
  • rarely (from ≥1 / 10000 to <1/1 000)
  • very rarely (<1/10 000) unknown (impossible to estimate based on available data).
  • Adverse reactions are presented in the table in accordance with the classification of organ systems in order of decreasing their clinical significance.

List of side effects of Bimatoprost 0.03%

Organ system Frequency Side reaction!
From the nervous system Infrequently Headache
is unknown dizziness
From the side of the organs of vision very often conjunctival hyperemia
Often Speckled keratitis, irritation of the mucous membrane of the eye, itching of the eyes, eyelash enlargement, eye pain, redness of the eyelids, itching of the eyelids
Infrequently Asthenopia, visual impairment, conjunctival dysfunction, conjunctival edema, iris hyperpigmentation, loss of eyelashes or eyebrows, swelling of the eyelids
is unknown Eyelid pigmentation, macular edema, periorbital changes and eyelid changes, including deepening of the eyelid furrow, dry eyes, discharge from the eye, eye swelling, foreign body sensation in the eye, increased lacrimation, eye discomfort, photophobia
Respiratory, thoracic and mediastinal disorders is unknown Asthma, exacerbation of asthma, exacerbation of chronic obstructive pulmonary disease (COPD) and shortness of breath
From the digestive tract Infrequently nausea
From the skin and subcutaneous tissues Often Hyperpigmentation of the skin, hypertrichosis
Infrequently Dry skin, crusting on the edge of the eyelids, itching
is unknown Skin color change (around the eyes)
General violations and changes in the place of administration Often Irritation at the injection site
From the immune system is unknown Hypersensitivity reaction, including symptoms of eye allergy and allergic dermatitis
From the vascular system is unknown High blood pressure

Additional information from

  • Keep these and all other medications out of the reach of children, never give your medications to others, and use Bimatoprost only as directed by a doctor.
  • Always consult with your doctor to make sure that the information displayed on this page can be applied to your personal circumstances.
  • If more than one local ophthalmic drug is used, it is necessary to take a 5-minute break between each instillation.
  • When the receptors are activated, the utilization of low-density cholesterol increases, which cleanses the bloodstream system of free lipid molecules.
  • If unusual symptoms occur during treatment, visual acuity has decreased, the eye has been injured or infected, it is recommended to contact an ophthalmologist and decide whether to discontinue treatment.
  • If an allergic reaction or hypersensitivity reaction occurs, it is necessary to seek medical help. Possible symptoms of such reactions include: difficulty breathing, difficulty swallowing, swelling, a feeling of tightness in the chest, skin rashes and urticaria.
  • This drug should be used only in accordance with the instructions and prescriptions of the attending physician or pharmacist. Do not change the dosage yourself without prescribing a doctor or pharmacist.
  • Dosage and use often depend on the severity of the disease, as well as on previous illnesses and the current state of health of the patient.Before taking this drug, it is necessary to inform the doctor about:
      pregnancy or breast-feeding;
      the presence of any allergies;
      the presence of any other diseases, disorders or disorders;
      taking any other medications or medications;
      taking any vitamins or dietary supplements.
  • Before starting treatment, patients should be informed about the possible increase in eyelashes, increased pigmentation of the eyelash skin and pigmentation of the iris, since these effects have been established during studies of the drug Bimatoprost. Some changes may be permanent and may be accompanied by differences between the eyes if the instillation of the drug was carried out only in one eye.
  • The use of Bimatoprost in patients with impaired respiratory function has not been studied, and therefore it should be prescribed with caution to this group of patients. In the course of clinical studies in patients with impaired respiratory function, there were no significant adverse effects on respiratory function in the anamnesis.
  • The use of Bimatoprost in patients with heart block or with uncontrolled congestive heart failure has not been investigated. Bimatoprost should be used with caution in patients prone to low heart rate or low blood pressure.
  • The use of Bimatoprost in patients with inflammatory eye diseases, neovascular, inflammatory, angle-closure, congenital glaucoma or narrow-angle glaucoma has not been investigated.
  • Bimatoprost should be used with caution in patients at risk of macular edema (with aphakia, pseudophakia with damage to the posterior capsule of the lens).
  • Bimatoprost should be used with caution in patients with a history of viral eye infections (for example, herpes simplex) or uveitis / inflammation of the iris.
  • Hair growth is possible in areas of the skin where the drug constantly comes into contact with the skin. It is necessary to use Bimatoprost according to the instructions for use and do not allow the drug to get on the skin.
  • There have been reports of bacterial keratitis associated with the use of multi-dose containers for topical ophthalmic products. These containers were accidentally contaminated by patients who, in most cases, had concomitant eye disease. Patients with rupture of the ocular epithelial surface are at greater risk of developing bacterial keratitis.
  • Benzalkonium chloride has been reported to cause speckled keratopathy and/or toxic ulcerative keratopathy. Since Bimatoprost, 0.1 mg/ml, contains benzalkonium chloride, it should be used with caution in patients with dry eye syndrome, with corneal damage and in patients who use several medications containing benzalkonium chloride in the form of eye drops. In addition, it is necessary to monitor the condition of patients with prolonged treatment with the drug.
  • The use of Bimatoprost in patients with moderate to severe renal or hepatic impairment has not been investigated. Therefore, caution should be exercised when treating patients of this group. In patients with a moderate history of liver dysfunction or abnormal indicators of AlAT, AsAT and / or bilirubin, the normal use of bimatoprost in the form of eye drops led to the development of side effects from the liver for 24 months.
  • The use of more than 1 dose of bimatoprost per day leads to a decrease in the severity of the effect of reducing increased intraocular pressure in patients with glaucoma or in patients with increased intraocular pressure. Patients who use Bimatoprost with other prostaglandin analogues should be under the supervision of a doctor and check intraocular pressure.
  • If more than one local ophthalmic drug is used, it is necessary to take a 5-minute break between each instillation.
  • Bimatoprost has little effect on the reaction speed when driving vehicles or working with other mechanisms. As with other eye drops, if temporary blurred vision occurs after instillation, the patient must wait until vision is restored before driving vehicles or working with other mechanisms.